Javascript must be enabled to continue!
Outcomes of Critically Ill Adult Patients With Acute Encephalitis
View through CrossRef
ImportanceFunctional outcomes and long-term recovery after severe encephalitis are not well characterized.ObjectiveTo determine the incidence of functional disability or death at 3 months and to describe recovery trajectories through 1 year after encephalitis.Design, Setting, and ParticipantsThis prospective multicenter cohort study was conducted across 31 French centers from October 2017 to April 2021 and included adults with probable or confirmed encephalitis and clear cerebrospinal fluid findings requiring care in the intensive care unit. Data analysis was performed between May 2023 and June 2025.ExposureCauses of encephalitis were categorized into 4 different groups: infectious, autoimmune, other causes, and unknown origin.Main Outcomes and MeasuresThe primary end point was an unfavorable outcome at 3 months, defined by a modified Rankin scale score of 3 to 6, indicating moderate to severe disability or death.ResultsAmong the 310 patients included (median [IQR] age, 60 [43-70] years; 177 male [57.1%]), 123 (39.7%) were diagnosed with infectious encephalitis, 42 (13.5%) with autoimmune encephalitis, 37 (11.9%) with other encephalitis causes, and 108 (34.8%) with encephalitis of unknown origin. Overall, 161 patients (51.9%; 95% CI, 46.2%-57.6%) had an unfavorable outcome at 3 months, including 84 deaths (27.1%). Independent factors associated with unfavorable outcome included age (odds ratio [OR] per 5-year increment, 1.28, 95% CI, 1.16 to 1.41) and immunocompromised status (OR, 3.12; 95% CI, 1.57 to 6.40), while intravenous acyclovir on the day of ICU admission was associated with a favorable outcome (OR, 0.38; 95% CI, 0.20 to 0.72). The proportion of patients achieving functional independence remained stable from 3 months to 1 year (difference in proportions, 1.1%; 95% CI, −6.9% to 9.2%). Analyses based on encephalitis cause groups revealed that patients with autoimmune encephalitis showed significant improvement through 1 year (difference in proportions, 8.9%; 95% CI, 1.2% to 16.6%), whereas no significant changes were seen in patients with infectious causes (difference in proportions, 1.2%; 95% CI, −6.9% to 9.2%), other causes (difference in proportions, 1.2%; 95% CI: −6.8% to 9.2%), or unknown origin (difference in proportions, −1.9%; 95% CI: −10.0% to 6.2%).Conclusions and RelevanceIn this cohort study of adults with severe encephalitis requiring intensive care, one-half of patients had an unfavorable outcome at 3 months. Functional recovery at 1 year varied by cause of encephalitis, with patients with autoimmune encephalitis experiencing more favorable outcomes than those with other causes, suggesting a possible role for targeted long-term support in certain cases.
American Medical Association (AMA)
Romain Sonneville
Camille Couffignal
Bertrand Souweine
Suela Demiri
Nicolas Terzi
Fabrice Bruneel
Armand Mekontso Dessap
Maelle Martin
Clémence Marois
Pierre Bailly
Achille Kouatchet
Guillaume Voiriot
Florian Reizine
Sarah Benghanem
Guillaume Louis
Marie Conrad
Sami Hraiech
Arnaud W. Thille
Jean-Christophe Navellou
Damien Contou
Simon Bourcier
Marc Tran
Frederic Dailler
Laurent Argaud
Charles Cerf
Bertrand Guidet
Damien Roux
Lionel Kerhuel
Guillaume Van Der Meersch
Saad Nseir
Adrien Joseph
Daniel Da Silva
Pascal Beuret
Benjamine Sarton
Candice Estellat
Virginie Godard
Jérôme Honnorat
Philippa Catherine Lavallée
Marina Esposito-Farèse
Jean-François Timsit
Moustafa ABDEL-NABEY
Melanie ADDA
Hamou Zakaria AIT
Virginie ANZANO
Romain ARRESTIER
Pierre ASFAR
Claire BACHELIER
François BAGATE
Elodie BARON
Thomas BAUDRY
François BELONCLE
Morgan BENAIS
Ines BENDIB
Brice BENELLI
Sarah BENGHANEM
Helene BERINGUER
Enora BERTI
Astrid BERTIER
Morage BERTRIX
Sebastien BESSET
Alexandra BEURTON
Naike BIGE
Clarisse BLAYAU
Florence BOISSIER
Pierre-Edouard BOLLAERT
Marjolaine BOREL
Lila BOUADMA
Athenais BOUCLY
Simon BOURCIER
Radhia BOUZGARROU
Cedric BRUEL
Côme BUREAU
Cyril CADOZ
Laure CALVET
Emmanuel CANET
Albert CAO
Alain CARIOU
Romain CARRILLON
Pedro CAVALEIRO
Julien CHARPENTIER
Delphine CHATELLIER
Vibol CHHOR
Jean-Daniel CHICHE
Sebastien CLERC
Benjamin COIFFARD
Remi COUDROY
Pierre COUHAULT
Elisabeth COUPEZ
Guilhem COURTE
Aurélie CRAVOISY-POPOVIC
Thibault CREUTIN
Laura CROSBY
Silva Daniel DA
Florence DAVIET
Montmollin Etienne DE
Maxens DECAVELE
Thecle DEGROOTE
Robin DELERIS
Sophie DEMERET
Suela DEMIRI
Julien DEMISELLE
Martin DRES
Louis-Marie DUMONT
Julien DUPEYRAT
Pierre DUPLAND
Claire DUPUIS
Kalioubie Ahmed EL
Morgane FAURE
Laura FEDERICI
Alexis FERRE
Jean-Marie FOREL
Guillaume FRANCHINEAU
Jean-Pierre FRAT
Santiago FREITA-RAMOS
Rostane GACI
Arnaud GACOUIN
Aude GARIN
Charlotte GARRET
Ariane GAVAUD
Segolene GENDREAU
Etienne GHRENASSIA
Sebastien GIBOT
Armelle GILARD
Tiphaine GIRARD
Florent GOBERT
Kevin GRAPIN
Christophe GUERVILLY
Marion HALLARD
Geoffroy HARIRI
Otto HARTMAN
Anne-Fleur HAUDEBOURG
Luc HAUDEBOURG
Jeremy HEBRAUD
Jérôme HONNORAT
Pierre JAQUET
Paul JAUBERT
Florent JOLY
Matthieu JOZWIAK
Hélène JULIEN
Francis KINDA
Pascale LABEDADE
Pascale LABROCA
Guillaume LACAVE
Driss LAGHLAM
Pauline LAMOUCHE-WILQUIN
Jean-Baptiste LASCARROU
Virginie LAURENT
Guillaume LAURICHESSE
Guennec Loïc LE
Marec Julien LE
Marie LECRONIER
Lucie LEFEVRE
Camille LEGOUY
Stephane LEGRIEL
Jérémie LEMARIE
Marie LEMERLE
Jean-Mathias LITEAUDON
Julien LOPINTO
Charles-Edouard LUYT
Adel MAAMAR
Assadi MAKSUD
Damien MARIE
Eric MARIOTTE
Remy MARNAI
Olivier MARTIN
Paul MASI
Rafael MATHIEU
Eric MAURY
Julien MAYAUX
Sandie MAZERAND
Alain MERCAT
Sybille MERCERON
Arnaud-Félix MIAILHE
Gael MICHAUD
Hélène MIGUERES
Jean-Paul MIRA
Grégoire MONSEAU
Elise MORAWIEC
Jean MORIN
Satar MORTAZA
Lionel NACE
Safaa NEMLAGHI
Mathilde NEUVILLE
Bao-Long NGUYEN
Lee NGUYEN
Pierre-Yves OLIVIER
Gregoire OTTAVY
Laurent PAPAZIAN
Edwidge PEJU
Frederic PENE
François PERIER
François PHILIPPART
Marc PIERROT
Olivier POULY
Gwenael PRAT
Simona PRESENTE
Isabelle PRIOUR
Thomas RAMBAUD
Keyvan RAZAZI
Jean REIGNIER
Anne RENAULT
Thomas RITZENTHALER
Alexandre ROBERT
Benjamin ROHAUT
Guillaume SAVARY
Faiza SAYAGH
Carole SCHWEBEL
Amélie SEGUIN
Stein SILVA
Fabrice SINNAH
Vincent SOUDAY
Françoise THOUY
Jean-Marie TONNELIER
Aurelia TOUSSAINT
Marc TRAN
Samuel TUFFET
Fabrice UHEL
Thomas URBINA
Anne VEINSTEIN
Charles VERNEY
Antoine VIEILLARD-BARON
Clara VIGNERON
Helene VINOUR
Sara VIROLLE
Lev VOLKOV
Constance VUILLARD
Nicolas WEISS
Paul Henri WICKY
Lara ZAFRANI
Olivier ZAMBON
Noemie ZUCMAN
Title: Outcomes of Critically Ill Adult Patients With Acute Encephalitis
Description:
ImportanceFunctional outcomes and long-term recovery after severe encephalitis are not well characterized.
ObjectiveTo determine the incidence of functional disability or death at 3 months and to describe recovery trajectories through 1 year after encephalitis.
Design, Setting, and ParticipantsThis prospective multicenter cohort study was conducted across 31 French centers from October 2017 to April 2021 and included adults with probable or confirmed encephalitis and clear cerebrospinal fluid findings requiring care in the intensive care unit.
Data analysis was performed between May 2023 and June 2025.
ExposureCauses of encephalitis were categorized into 4 different groups: infectious, autoimmune, other causes, and unknown origin.
Main Outcomes and MeasuresThe primary end point was an unfavorable outcome at 3 months, defined by a modified Rankin scale score of 3 to 6, indicating moderate to severe disability or death.
ResultsAmong the 310 patients included (median [IQR] age, 60 [43-70] years; 177 male [57.
1%]), 123 (39.
7%) were diagnosed with infectious encephalitis, 42 (13.
5%) with autoimmune encephalitis, 37 (11.
9%) with other encephalitis causes, and 108 (34.
8%) with encephalitis of unknown origin.
Overall, 161 patients (51.
9%; 95% CI, 46.
2%-57.
6%) had an unfavorable outcome at 3 months, including 84 deaths (27.
1%).
Independent factors associated with unfavorable outcome included age (odds ratio [OR] per 5-year increment, 1.
28, 95% CI, 1.
16 to 1.
41) and immunocompromised status (OR, 3.
12; 95% CI, 1.
57 to 6.
40), while intravenous acyclovir on the day of ICU admission was associated with a favorable outcome (OR, 0.
38; 95% CI, 0.
20 to 0.
72).
The proportion of patients achieving functional independence remained stable from 3 months to 1 year (difference in proportions, 1.
1%; 95% CI, −6.
9% to 9.
2%).
Analyses based on encephalitis cause groups revealed that patients with autoimmune encephalitis showed significant improvement through 1 year (difference in proportions, 8.
9%; 95% CI, 1.
2% to 16.
6%), whereas no significant changes were seen in patients with infectious causes (difference in proportions, 1.
2%; 95% CI, −6.
9% to 9.
2%), other causes (difference in proportions, 1.
2%; 95% CI: −6.
8% to 9.
2%), or unknown origin (difference in proportions, −1.
9%; 95% CI: −10.
0% to 6.
2%).
Conclusions and RelevanceIn this cohort study of adults with severe encephalitis requiring intensive care, one-half of patients had an unfavorable outcome at 3 months.
Functional recovery at 1 year varied by cause of encephalitis, with patients with autoimmune encephalitis experiencing more favorable outcomes than those with other causes, suggesting a possible role for targeted long-term support in certain cases.
Related Results
Encephalitis lethargica: clinical features and aetiology
Encephalitis lethargica: clinical features and aetiology
Abstract
Encephalitis lethargica, an epidemic neurological illness, typically involved a severe sleep disorder and progressive parkinsonism. A century later, our und...
Trends in Encephalitis-Associated Deaths in the United States, 1999-2008
Trends in Encephalitis-Associated Deaths in the United States, 1999-2008
<b><i>Background:</i></b> While encephalitis may be caused by numerous infectious, immune and toxic processes, the etiology often remains unknown. <b>...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Biomarkers in critically ill patients
Biomarkers in critically ill patients
We investigated whether biomarkers could (1) improve early diagnosis of sepsis (2) predict prognosis in patients with pneumonia and aneurysmal subarachnoid hemorrhage, (3) predict ...
High sensitivity and specificity in proposed clinical diagnostic criteria for anti‐N‐methyl‐D‐aspartate receptor encephalitis
High sensitivity and specificity in proposed clinical diagnostic criteria for anti‐N‐methyl‐D‐aspartate receptor encephalitis
AimTo determine the validity of the proposed clinical diagnostic criteria for anti‐N‐methyl‐d‐aspartate receptor (NMDAR) encephalitis in paediatric patients.MethodThe diagnostic cr...
Importance of vitamin D in critically ill children with subgroup analyses of sepsis and respiratory tract infections: a systematic review and meta-analysis
Importance of vitamin D in critically ill children with subgroup analyses of sepsis and respiratory tract infections: a systematic review and meta-analysis
SummaryBackgroundCritical care and sepsis remain high priority concerns in children. Observational studies report high prevalence of vitamin D deficiency and present mixed results ...
Mental health outcomes of encephalitis: an international web-based study
Mental health outcomes of encephalitis: an international web-based study
AbstractEncephalitis is associated with psychiatric symptoms in the acute and post-acute stages, and many survivors experience long-term sequelae. Despite this, the breadth and sev...
Human Viral Encephalitis Associated With Suid Herpesvirus 1
Human Viral Encephalitis Associated With Suid Herpesvirus 1
Abstract
Background: Suid herpesvirus type 1 (SHV1) is a type of neurotropic virus able to infect various species. However, the clinical cases of human SHV1 encephalitis ar...

